Full Title
A Phase I/II Study of the Safety, Tolerability and Efficacy of Belantamab Mafodotin (GSK2857916) in Combination with Iberdomide (CC-220)/Dexamethasone Versus Belantamab Mafodotin (GSK2857916)/Dexamethasone in Relapsed Refractory Multiple Myeloma (A062101) (CIRB)Purpose
Researchers are assessing the iberdomide with belantamab mafodotin and dexamethasone in people with multiple myeloma. The people in this study have multiple myeloma that came back or keeps growing even with treatment.
Multiple myeloma cells have a protein on their surface called BCMA, which allows them to survive and grow. Belantamab mafodotin attaches to BCMA, which may cause myeloma cells to become damaged and die. Iberdomide is an immunotherapy that may promote changes in the immune system and may interfere with cancer growth.
If you join this study, you will be randomly assigned to get one of these treatments:
- Belantamab mafodotin and dexamethasone plus iberdomide
- Belantamab mafodotin and dexamethasone
Belantamab mafodotin is given intravenously (by vein), and iberdomide and dexamethasone are taken orally (by mouth).
Who Can Join
To join this study, there are a few conditions. You must:
- Have multiple myeloma that came back or keeps growing despite at least two regimens of treatment. Prior treatment may not have included belantamab mafodotin, iberdomide, or a donated stem cell transplant.
- Be able to walk and do routine activities for more than half the time you are awake.
- Be age 18 or older.
Contact
For more information or to see if you can join this study, please call Dr. Saad Usmani’s office at 646-608-4165.